| Lastest Insider Transactions Of Apellis Pharmaceuticals, Inc. ( APLS ) |
| Symbol | Company Name | Insider Name | Title | Date | Transation | Share | Price | Amount | File Date |
| APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | 2026-01-22 | Sell | 2,797 | 21.77 | 60,878 | 2026-01-23 16:13:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2026-01-22 | Sell | 2,064 | 21.77 | 44,924 | 2026-01-23 16:12:41 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2026-01-22 | Sell | 3,371 | 21.77 | 73,371 | 2026-01-23 16:11:33 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2026-01-22 | Sell | 5,928 | 21.77 | 129,025 | 2026-01-23 16:10:37 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2026-01-22 | Sell | 27,192 | 21.77 | 591,845 | 2026-01-23 16:09:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2026-01-22 | Sell | 7,725 | 21.77 | 168,138 | 2026-01-23 16:08:15 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2026-01-22 | Sell | 10,287 | 21.77 | 223,901 | 2026-01-23 16:07:20 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2026-01-22 | Sell | 7,832 | 21.77 | 170,467 | 2026-01-23 16:05:32 |
| APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | 2026-01-20 | Sell | 1,882 | 19.79 | 37,250 | 2026-01-21 16:19:30 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2026-01-20 | Sell | 726 | 19.79 | 14,370 | 2026-01-21 16:18:30 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2026-01-20 | Sell | 1,334 | 19.79 | 26,404 | 2026-01-21 16:17:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2026-01-20 | Sell | 909 | 19.79 | 17,992 | 2026-01-21 16:16:30 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2026-01-20 | Sell | 8,182 | 19.79 | 161,946 | 2026-01-21 16:14:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2026-01-20 | Sell | 2,203 | 19.79 | 43,604 | 2026-01-21 16:12:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2026-01-20 | Sell | 2,892 | 19.79 | 57,241 | 2026-01-21 16:10:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2026-01-20 | Sell | 2,475 | 19.79 | 48,987 | 2026-01-21 16:08:22 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2026-01-13 | Sell | 873 | 22.19 | 19,369 | 2026-01-15 16:34:40 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2026-01-13 | Sell | 1,780 | 22.19 | 39,493 | 2026-01-15 16:33:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2026-01-13 | Sell | 2,277 | 22.19 | 50,520 | 2026-01-15 16:32:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2026-01-13 | Sell | 10,186 | 22.19 | 225,999 | 2026-01-15 16:31:07 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2026-01-13 | Sell | 2,618 | 22.19 | 58,086 | 2026-01-15 16:30:08 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2026-01-13 | Sell | 3,856 | 22.19 | 85,554 | 2026-01-15 16:29:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2026-01-13 | Sell | 5,780 | 22.19 | 128,242 | 2026-01-15 16:28:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2026-01-07 | Option Exercise | 888 | 14.95 | 13,276 | 2026-01-09 18:48:43 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-12-16 | Sell | 5,000 | 24.49 | 122,450 | 2025-12-18 16:06:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-11-17 | Sell | 5,000 | 20.06 | 100,300 | 2025-11-18 10:05:23 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-10-21 | Sell | 10,000 | 28.03 | 280,300 | 2025-10-23 16:20:30 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-10-21 | Option Exercise | 10,000 | 10.03 | 100,300 | 2025-10-23 16:20:30 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-10-16 | Sell | 5,000 | 25.22 | 126,100 | 2025-10-17 16:15:08 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2025-06-24 | Sell | 31,092 | 23.72 | 737,536 | 2025-10-15 20:12:04 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2025-09-30 | Sell | 31,092 | 22.58 | 702,057 | 2025-10-02 16:02:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2025-09-19 | Sell | 31,092 | 22.95 | 713,561 | 2025-09-19 21:17:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-09-16 | Sell | 5,000 | 24.34 | 121,700 | 2025-09-18 16:01:10 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2025-09-15 | Sell | 189 | 24.19 | 4,572 | 2025-09-17 20:08:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-09-08 | Sell | 42,729 | 27.85 | 1,190,130 | 2025-09-10 16:02:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-09-08 | Option Exercise | 15,000 | 10.03 | 150,450 | 2025-09-10 16:02:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-09-08 | Sell | 42,729 | 27.85 | 1,190,130 | 2025-09-10 16:02:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-09-08 | Option Exercise | 15,000 | 10.03 | 150,450 | 2025-09-10 16:02:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2025-09-02 | Sell | 548 | 28.08 | 15,386 | 2025-09-03 13:06:28 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-08-27 | Sell | 225,000 | 28.23 | 6,352,743 | 2025-08-29 16:19:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-08-18 | Sell | 5,000 | 27.80 | 139,000 | 2025-08-19 16:40:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-07-17 | Sell | 19,725 | 20.21 | 398,735 | 2025-07-18 16:02:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-07-17 | Option Exercise | 8,997 | 4.31 | 38,777 | 2025-07-18 16:02:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-07-16 | Sell | 5,000 | 19.55 | 97,750 | 2025-07-18 16:00:54 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-07-14 | Sell | 139,365 | 20.19 | 2,813,092 | 2025-07-16 16:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-07-14 | Option Exercise | 66,003 | 4.31 | 284,473 | 2025-07-16 16:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-06-16 | Sell | 5,000 | 18.77 | 93,850 | 2025-06-18 08:49:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2025-05-21 | Option Exercise | 12,780 | 3.76 | 48,053 | 2025-05-22 13:19:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2025-03-17 | Sell | 183 | 24.82 | 4,543 | 2025-03-18 12:27:02 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-03-04 | Sell | 5,569 | 25.10 | 139,789 | 2025-03-06 17:17:05 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2025-02-11 | Sell | 363 | 28.54 | 10,360 | 2025-02-12 13:59:21 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-01-29 | Sell | 695 | 29.52 | 20,519 | 2025-01-30 12:20:07 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2025-01-29 | Sell | 695 | 29.52 | 20,519 | 2025-01-30 12:18:22 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-01-29 | Sell | 546 | 29.52 | 16,120 | 2025-01-30 12:15:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2025-01-29 | Sell | 825 | 29.52 | 24,357 | 2025-01-30 12:13:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2025-01-29 | Sell | 364 | 29.52 | 10,747 | 2025-01-30 12:12:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2025-01-29 | Sell | 278 | 29.52 | 8,208 | 2025-01-30 12:10:43 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2025-01-29 | Sell | 826 | 29.52 | 24,386 | 2025-01-30 12:07:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-01-29 | Sell | 2,824 | 29.52 | 83,375 | 2025-01-30 12:03:08 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2025-01-29 | Sell | 365 | 29.52 | 10,776 | 2025-01-30 12:01:02 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-01-22 | Sell | 3,323 | 30.43 | 101,104 | 2025-01-23 15:41:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2025-01-22 | Sell | 3,323 | 30.43 | 101,104 | 2025-01-23 15:39:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-01-22 | Sell | 3,088 | 30.43 | 93,954 | 2025-01-23 15:37:07 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2025-01-22 | Sell | 3,948 | 30.43 | 120,120 | 2025-01-23 15:31:08 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2025-01-22 | Sell | 1,751 | 30.43 | 53,275 | 2025-01-23 15:29:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-01-22 | Sell | 13,551 | 30.43 | 412,296 | 2025-01-23 15:28:15 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2025-01-22 | Sell | 1,291 | 30.43 | 39,279 | 2025-01-23 15:26:42 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2025-01-22 | Sell | 3,948 | 30.43 | 120,120 | 2025-01-23 15:25:12 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2025-01-22 | Sell | 1,396 | 30.43 | 42,474 | 2025-01-23 15:23:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2025-01-22 | Sell | 1,096 | 30.43 | 33,346 | 2025-01-23 15:19:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-01-17 | Sell | 2,201 | 29.96 | 65,938 | 2025-01-21 16:14:27 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2025-01-17 | Sell | 2,201 | 29.96 | 65,938 | 2025-01-21 16:12:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-01-17 | Sell | 1,730 | 29.96 | 51,828 | 2025-01-21 16:11:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2025-01-17 | Sell | 2,145 | 29.96 | 64,260 | 2025-01-21 16:09:04 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2025-01-17 | Sell | 1,241 | 29.96 | 37,178 | 2025-01-21 16:07:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-01-17 | Sell | 6,007 | 29.96 | 179,959 | 2025-01-21 16:04:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2025-01-17 | Sell | 750 | 29.96 | 22,469 | 2025-01-21 16:02:18 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2025-01-17 | Sell | 1,235 | 29.96 | 36,998 | 2025-01-21 15:59:13 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2025-01-17 | Sell | 715 | 29.96 | 21,420 | 2025-01-21 15:56:58 |
| APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | 2025-01-17 | Sell | 1,853 | 29.96 | 55,513 | 2025-01-21 15:54:49 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2025-01-13 | Sell | 4,965 | 28.70 | 142,506 | 2025-01-14 16:30:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2025-01-13 | Sell | 2,685 | 28.70 | 77,065 | 2025-01-14 16:29:19 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2025-01-13 | Sell | 2,170 | 28.70 | 62,284 | 2025-01-14 16:25:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2025-01-13 | Sell | 2,632 | 28.70 | 75,544 | 2025-01-14 16:22:49 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2025-01-13 | Sell | 1,599 | 28.70 | 45,895 | 2025-01-14 16:20:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2025-01-13 | Sell | 6,247 | 28.70 | 179,302 | 2025-01-14 16:18:10 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2025-01-13 | Sell | 264 | 28.70 | 7,577 | 2025-01-14 16:15:55 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2025-01-13 | Sell | 2,288 | 28.70 | 65,670 | 2025-01-14 16:14:08 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2025-01-13 | Sell | 1,599 | 28.70 | 45,895 | 2025-01-14 16:10:42 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2025-01-13 | Sell | 783 | 28.70 | 22,474 | 2025-01-14 16:09:26 |
| APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | 2025-01-06 | Sell | 2,816 | 33.81 | 95,215 | 2025-01-08 16:03:11 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-12-31 | Option Exercise | 11,096 | 13.95 | 154,826 | 2025-01-03 16:09:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-12-23 | Sell | 63 | 33.09 | 2,085 | 2024-12-27 16:06:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-09-23 | Option Exercise | 4,600 | 13.19 | 60,674 | 2024-09-24 16:20:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-09-16 | Sell | 37,000 | 36.23 | 1,340,597 | 2024-09-17 17:21:32 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-09-16 | Sell | 192 | 36.21 | 6,952 | 2024-09-17 16:08:51 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-08-12 | Option Exercise | 5,201 | 13.85 | 72,034 | 2024-08-13 16:13:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-06-28 | Option Exercise | 900 | 13.19 | 11,871 | 2024-07-01 16:02:27 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-06-21 | Sell | 37,000 | 39.24 | 1,451,835 | 2024-06-21 19:34:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-05-20 | Option Exercise | 24,500 | 3.76 | 92,120 | 2024-05-21 16:03:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-05-08 | Sell | 78,907 | 42.35 | 3,341,848 | 2024-05-09 17:15:23 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-05-08 | Option Exercise | 78,907 | 4.31 | 340,089 | 2024-05-09 17:15:23 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-04-12 | Option Exercise | 1,500 | 13.19 | 19,785 | 2024-04-15 16:09:49 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-04-08 | Sell | 69,107 | 54.17 | 3,743,605 | 2024-04-09 16:25:25 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-04-08 | Option Exercise | 69,107 | 3.76 | 259,842 | 2024-04-09 16:25:25 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-04-01 | Sell | 4,000 | 58.66 | 234,640 | 2024-04-02 16:06:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-04-01 | Option Exercise | 4,000 | 10.03 | 40,120 | 2024-04-02 16:06:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2024-03-19 | Sell | 18,681 | 57.18 | 1,068,161 | 2024-03-20 17:18:54 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-03-18 | Sell | 9,913 | 56.90 | 564,050 | 2024-03-19 16:03:44 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-03-15 | Sell | 184 | 56.46 | 10,389 | 2024-03-18 16:19:22 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-03-13 | Sell | 11,220 | 57.56 | 645,838 | 2024-03-14 16:17:21 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-03-08 | Sell | 69,107 | 62.19 | 4,297,549 | 2024-03-11 16:08:32 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-03-08 | Option Exercise | 69,107 | 3.67 | 253,623 | 2024-03-11 16:08:32 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-03-06 | Option Exercise | 3,762 | 13.85 | 52,104 | 2024-03-08 07:45:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-03-01 | Sell | 250,000 | 64.11 | 16,028,706 | 2024-03-05 16:07:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-03-01 | Option Exercise | 250,000 | 4.20 | 1,050,000 | 2024-03-05 16:07:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-02-12 | Sell | 781 | 67.77 | 52,926 | 2024-02-13 17:06:56 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-02-12 | Sell | 1,148 | 67.77 | 77,796 | 2024-02-13 17:05:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-02-12 | Sell | 1,431 | 67.77 | 96,974 | 2024-02-13 16:59:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-02-12 | Sell | 3,962 | 67.77 | 268,492 | 2024-02-13 16:49:52 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-02-12 | Sell | 1,148 | 67.77 | 77,796 | 2024-02-13 16:43:13 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-02-12 | Sell | 597 | 67.77 | 40,457 | 2024-02-13 16:38:13 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-01-29 | Sell | 906 | 64.14 | 58,109 | 2024-01-31 16:38:44 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-01-29 | Sell | 906 | 64.14 | 58,109 | 2024-01-31 16:36:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-01-29 | Sell | 906 | 64.14 | 58,109 | 2024-01-31 16:34:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-01-29 | Sell | 835 | 64.14 | 53,555 | 2024-01-31 16:31:31 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-29 | Sell | 1,250 | 65.12 | 81,402 | 2024-01-31 16:28:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-01-29 | Sell | 2,843 | 64.14 | 182,345 | 2024-01-31 16:26:28 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-29 | Sell | 1,250 | 65.22 | 81,524 | 2024-01-31 16:23:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-01-29 | Sell | 874 | 64.14 | 56,057 | 2024-01-31 16:21:06 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-01-29 | Sell | 367 | 64.14 | 23,539 | 2024-01-31 16:18:50 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-23 | Sell | 4,286 | 63.69 | 272,975 | 2024-01-24 16:06:20 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-23 | Sell | 7,378 | 63.69 | 469,905 | 2024-01-24 16:03:55 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-01-22 | Sell | 13,431 | 65.00 | 872,961 | 2024-01-23 19:28:59 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-01-22 | Sell | 4,184 | 65.00 | 271,943 | 2024-01-23 18:17:03 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-01-22 | Sell | 3,413 | 65.00 | 221,831 | 2024-01-23 18:15:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-01-22 | Sell | 3,551 | 65.00 | 230,801 | 2024-01-23 18:13:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-01-22 | Sell | 2,593 | 65.00 | 168,535 | 2024-01-23 18:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-22 | Sell | 1,738 | 65.00 | 112,963 | 2024-01-23 18:07:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-22 | Sell | 1,607 | 65.00 | 104,449 | 2024-01-23 18:05:11 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-01-22 | Sell | 3,913 | 65.00 | 254,329 | 2024-01-23 18:03:25 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-01-22 | Sell | 1,384 | 65.00 | 89,954 | 2024-01-23 18:01:42 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-01-22 | Sell | 1,061 | 65.00 | 68,961 | 2024-01-23 18:00:05 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-17 | Sell | 5,207 | 65.58 | 341,475 | 2024-01-18 16:55:06 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-17 | Sell | 3,276 | 65.58 | 214,840 | 2024-01-18 16:54:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2024-01-16 | Sell | 1,632 | 66.81 | 109,032 | 2024-01-17 16:47:27 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2024-01-16 | Sell | 864 | 66.81 | 57,723 | 2024-01-17 16:45:04 |
| APLS | Apellis Pharmaceuticals, Inc. | Lewis Karen | Chief People Officer | 2024-01-16 | Sell | 1,632 | 66.81 | 109,032 | 2024-01-17 16:43:45 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2024-01-16 | Sell | 1,631 | 66.81 | 108,965 | 2024-01-17 16:41:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2024-01-16 | Sell | 1,857 | 66.81 | 124,064 | 2024-01-17 16:40:13 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2024-01-16 | Sell | 4,240 | 66.81 | 283,268 | 2024-01-17 16:38:41 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2024-01-16 | Sell | 2,235 | 66.81 | 149,317 | 2024-01-17 16:37:15 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2024-01-16 | Sell | 2,235 | 66.81 | 149,317 | 2024-01-17 16:36:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2024-01-16 | Sell | 7,851 | 66.81 | 524,514 | 2024-01-17 16:32:17 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2024-01-16 | Sell | 438 | 66.81 | 29,262 | 2024-01-17 12:24:09 |
| APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | 2024-01-04 | Sell | 2,751 | 60.05 | 165,207 | 2024-01-05 16:14:02 |
| APLS | Apellis Pharmaceuticals, Inc. | Eisele Jeffrey | Chief Development Officer | 2023-12-26 | Sell | 303 | 59.70 | 18,089 | 2023-12-28 16:13:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2023-12-19 | Sell | 3,905 | 57.23 | 223,472 | 2023-12-20 16:18:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2023-12-19 | Option Exercise | 7,905 | 13.85 | 109,484 | 2023-12-20 16:18:12 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-12-14 | Option Exercise | 6,274 | 13.19 | 82,754 | 2023-12-15 16:04:49 |
| APLS | Apellis Pharmaceuticals, Inc. | SCHEIBLER LUKAS | Chief Research Officer | 2023-12-01 | Sell | 10,000 | 60.00 | 600,000 | 2023-12-05 19:40:46 |
| APLS | Apellis Pharmaceuticals, Inc. | SCHEIBLER LUKAS | Chief Research Officer | 2023-12-01 | Option Exercise | 10,000 | 13.85 | 138,500 | 2023-12-05 19:40:46 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-12-01 | Sell | 110,000 | 60.81 | 6,689,304 | 2023-12-05 19:29:19 |
| APLS | Apellis Pharmaceuticals, Inc. | Townsend Adam J. | Chief Commercial Officer | 2023-12-01 | Option Exercise | 110,000 | 15.09 | 1,659,900 | 2023-12-05 19:29:19 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-12-01 | Sell | 24,000 | 61.13 | 1,467,240 | 2023-12-05 16:21:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-11-30 | Sell | 14,158 | 54.73 | 774,884 | 2023-12-01 16:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | Chief Financial Officer | 2023-11-30 | Option Exercise | 14,158 | 10.03 | 142,005 | 2023-12-01 16:11:00 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-11-21 | Sell | 5,000 | 48.80 | 244,000 | 2023-11-21 17:36:20 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-11-17 | Sell | 8,894 | 49.99 | 444,620 | 2023-11-21 16:36:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Directior | 2023-11-17 | Sell | 24,000 | 49.00 | 1,176,000 | 2023-11-21 16:00:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-11-17 | Sell | 1,250 | 47.74 | 59,675 | 2023-11-20 16:18:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-11-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-11-20 16:18:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-11-14 | Option Exercise | 45,000 | 3.76 | 169,200 | 2023-11-15 16:10:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-11-08 | Sell | 12,000 | 47.27 | 567,240 | 2023-11-09 16:18:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-11-08 | Option Exercise | 17,494 | 2.67 | 46,709 | 2023-11-09 16:18:16 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2023-10-23 | Sell | 132 | 46.04 | 6,077 | 2023-10-24 16:20:19 |
| APLS | Apellis Pharmaceuticals, Inc. | DeLong Mark Jeffrey | Chief Business & Strat Officer | 2023-10-23 | Sell | 131 | 46.04 | 6,031 | 2023-10-24 16:18:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-10-17 | Sell | 1,250 | 48.50 | 60,625 | 2023-10-18 17:43:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-10-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-10-18 17:43:35 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-10-09 | Sell | 12,000 | 40.38 | 484,560 | 2023-10-10 16:26:37 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-10-09 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-10-10 16:26:37 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-18 | Sell | 1,250 | 45.00 | 56,250 | 2023-09-19 17:05:52 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-18 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-09-19 17:05:52 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2023-09-18 | Sell | 20,350 | 44.27 | 900,813 | 2023-09-19 17:03:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | 2023-09-18 | Option Exercise | 9,719 | 29.76 | 289,237 | 2023-09-19 17:03:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-15 | Sell | 1,250 | 45.34 | 56,675 | 2023-09-18 16:24:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-09-15 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-09-18 16:24:24 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-09-08 | Sell | 12,000 | 42.87 | 514,440 | 2023-09-11 16:58:21 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-09-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-09-11 16:58:21 |
| APLS | Apellis Pharmaceuticals, Inc. | SCHEIBLER LUKAS | Chief Research Officer | 2023-09-06 | Sell | 1,756 | 43.01 | 75,526 | 2023-09-07 16:08:01 |
| APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP/Chief Accounting Officer | 2023-08-31 | Sell | 551 | 41.23 | 22,716 | 2023-09-01 16:08:14 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-09-01 | Sell | 150,000 | 41.75 | 6,262,960 | 2023-09-01 16:05:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | Chief Executive Officer | 2023-09-01 | Option Exercise | 300,000 | 2.67 | 801,000 | 2023-09-01 16:05:29 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-08-08 | Sell | 12,000 | 23.66 | 283,920 | 2023-08-09 16:08:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | 2023-08-08 | Option Exercise | 18,500 | 2.67 | 49,395 | 2023-08-09 16:08:18 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-21 | Option Exercise | 49,779 | 2.67 | 132,910 | 2023-07-24 17:01:36 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-20 | Option Exercise | 50,000 | 2.67 | 133,500 | 2023-07-21 16:13:34 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-17 | Sell | 1,250 | 64.79 | 80,988 | 2023-07-18 16:40:51 |
| APLS | Apellis Pharmaceuticals, Inc. | Machiels Alec | Directior | 2023-07-17 | Option Exercise | 1,250 | 2.67 | 3,338 | 2023-07-18 16:40:51 |
| APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | General Counsel | 2023-07-03 | Sell | 8,510 | 89.98 | 765,730 | 2023-07-06 16:20:15 |
